Cargando…

Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel

In the TRANSCEND NHL 001 study, 53% of patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) achieved a complete response (CR). To determine characteristics of patients who did and did not achieve a CR, we examined the tumor biology and micro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olson, N. Eric, Ragan, Seamus P., Reiss, David J., Thorpe, Jerill, Kim, Yeonhee, Abramson, Jeremy S., McCoy, Candice, Newhall, Kathryn J., Fox, Brian A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978882/ https://www.ncbi.nlm.nih.gov/pubmed/36595660 http://dx.doi.org/10.1158/1535-7163.MCT-21-0506

Ejemplares similares

Monitoring Circulating Tumor DNA During Surgical Treatment in Patients with Gastrointestinal Stromal Tumors
por: Johansson, Gustav, et al.
Publicado: (2021)

A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas
por: Shah, Avanthi Tayi, et al.
Publicado: (2021)

Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
por: Georgiev, Peter, et al.
Publicado: (2022)

Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible
por: Jensen, Taylor J., et al.
Publicado: (2021)

HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study
por: Osada, Takuya, et al.
Publicado: (2022)

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
por: Judd, Julia, et al.
Publicado: (2021)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
por: Mirza, Abu-Sayeef, et al.
Publicado: (2023)

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline
por: Davenport, J Michael, et al.
Publicado: (2015)

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
por: Imamura, Chiyo K., et al.
Publicado: (2015)

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects
por: Vourvahis, Manoli, et al.
Publicado: (2018)

CYP2B6*6 Genotype Specific Differences in Artemether‐Lumefantrine Disposition in Healthy Volunteers
por: Abdullahi, Sa'ad T., et al.
Publicado: (2019)

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
por: Marshall, Jean‐Claude, et al.
Publicado: (2021)

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
por: Abramson, Jeremy S., et al.
Publicado: (2023)

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2022)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2022)

Association between PHOX2B gene rs28647582 T>C polymorphism and Wilms tumor susceptibility
por: Lin, Ao, et al.
Publicado: (2019)

The association of miR34b/c and TP53 gene polymorphisms with Wilms tumor risk in Chinese children
por: Wang, Juxiang, et al.
Publicado: (2020)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL
por: Rasheed, Yusuf, et al.
Publicado: (2023)

Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
por: Parker, Christopher, et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
por: Cartron, Guillaume, et al.
Publicado: (2022)

Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients
por: Cheng, Daye, et al.
Publicado: (2020)

Comments on ‘Association of FcϵRIβ polymorphisms with risk of asthma and allergic rhinitis: evidence based on 29 case–control studies’
por: Yang, Haijun, et al.
Publicado: (2020)

Relationship between lncRNA-Ang362 and prognosis of patients with coronary heart disease after percutaneous coronary intervention
por: Wang, Hui, et al.
Publicado: (2020)

Fibrinogen is a promising biomarker for chronic obstructive pulmonary disease: evidence from a meta-analysis
por: Zhou, Bo, et al.
Publicado: (2020)

HN1 as a diagnostic and prognostic biomarker for liver cancer
por: Liu, Zhicheng, et al.
Publicado: (2020)

Ionizing radiation induces epithelial–mesenchymal transition in human bronchial epithelial cells
por: Tang, Bo, et al.
Publicado: (2020)

The efficacy of L-carnitine in improving malnutrition in patients on maintenance hemodialysis: a meta-analysis
por: Zhou, Jianwei, et al.
Publicado: (2020)

Common variants in LTBP3 gene contributed to the risk of hip osteoarthritis in Han Chinese population
por: Zhao, Tianyun, et al.
Publicado: (2020)

The clinical diagnostic value of Xpert MTB/RIF for the detection of Mycobacterium tuberculosis in gastric aspirates
por: Tan, Hong-Kun, et al.
Publicado: (2020)

Novel compound heterozygous EYS variants may be associated with arRP in a large Chinese pedigree
por: Wei, Chunli, et al.
Publicado: (2020)

Significant association between the endothelial lipase gene 584C/T polymorphism and coronary artery disease risk
por: Wu, Yue-e, et al.
Publicado: (2020)

Plasma lipidomic analysis of sphingolipids in patients with large artery atherosclerosis cerebrovascular disease and cerebral small vessel disease
por: You, Qian, et al.
Publicado: (2020)

Inflammatory and endothelial dysfunction indices among Egyptian females with obesity classes I–III
por: Mohamed, Amal Ahmed, et al.
Publicado: (2020)

miR-618 rs2682818 C>A polymorphism decreases Hirschsprung disease risk in Chinese children
por: Zheng, Yi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4q8unmifme9mmkhckfhj5ufeei